Last reviewed · How we verify
Lamivudine/Zidovudine
This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.
This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Lamivudine/Zidovudine |
|---|---|
| Also known as | 3TC/ZDV, Combivir, CBV, 3TC/AZT, ZDV/3TC |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lamivudine and zidovudine are both nucleoside analogs that inhibit HIV reverse transcriptase, the enzyme the virus uses to convert its RNA genome into DNA for integration into host cells. By competing with natural nucleotides, they cause chain termination during viral DNA synthesis, effectively blocking HIV replication. The combination provides synergistic antiviral activity and is used as part of combination antiretroviral therapy.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Headache
- Nausea
- Fatigue
- Anemia
- Neutropenia
- Lactic acidosis
- Lipoatrophy
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Reverse Transcriptase Inhibitors in AGS (PHASE2)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding (PHASE2)
- A Prospective Cohort of Children With HIV Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |